Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States

Hepatology

Volumn 61, Issue 5, 2015, Pages 1643-1650

  Heimbach, Julie K ^a   Hirose, Ryutaro ^b   Stock, Peter G ^b,c   Schladt, David P ^c   Xiong, Hui ^c   Liu, Jiannong ^c   Olthoff, Kim M ^d   Harper, Ann ^e   Snyder, Jon J ^c,f   Israni, Ajay K ^c,f,g   Kasiske, Bertram L ^c,g   Kim, W Ray ^c,h  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNITED NETWORK FOR ORGAN SHARING   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^h STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COMPUTER PROGRAM; DEMOGRAPHY; DISEASE REGISTRY; END STAGE LIVER DISEASE; FEMALE; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HEALTH CARE POLICY; HUMAN; LIVER CELL CARCINOMA; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; SCORING SYSTEM; THERAPY DELAY; UNITED STATES; CARCINOMA, HEPATOCELLULAR; HEALTH CARE DELIVERY; HOSPITAL ADMISSION; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PATIENT SELECTION; STATISTICS AND NUMERICAL DATA; THEORETICAL MODEL; TIME;

CARCINOMA, HEPATOCELLULAR; END STAGE LIVER DISEASE; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, THEORETICAL; PATIENT SELECTION; TIME FACTORS; UNITED STATES; WAITING LISTS;

EID: 84928204134     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27704     Document Type: Article

References (14)

1. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
2. Sharma P, Harper AM, Hernandez JL, Heffron T, Mulligan DC, Wiesner RH, et al. Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation. Am J Transplant 2006;6:1957-1962.
3. Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology 2004;127(5 Suppl. 1):S261-S267.
4. Washburn K, Edwards E, Harper A, Freeman R. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant 2010;10:1643-1648.
5. Massie AB, Caffo B, Gentry SE, Hall EC, Axelrod DA, Lentine KL, et al. MELD exceptions and rates of waiting list outcomes. Am J Transplant 2011;11:2362-2371.
6. Singal AK, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 2013;95:755-760.
7. Scientific Registry of Transplant Recipients. OPTN & SRTR 2012 Annual Data Report. Rockville, MD: US Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation.
8. Leppke S, Leighton T, Zaun D, Chen SC, Skeans M, Israni AK, et al. Scientific Registry of Transplant Recipients: collecting, analyzing, and reporting data on transplantation in the United States. Transplant Rev (Orlando) 2013;27:50-56.
9. Scientific Registry of Transplant Recipients. Liver Simulated Allocation Model (LSAM): User's Guide. Version 2014. http://www.srtr.org/sam/LSAM.pdf. Accessed December 29, 2014.
10. Organ Procurement and Transplantation Network. Policy 9.3.G Candidates with Hepatocellular Carcinoma (HCC) Effective 12/4/2014 http://optn.transplant.hrsa.gov/ContentDocuments/OPTN_Policies.pdf#nameddest=Policy_08.
11. Freeman RB Jr, Gish RG, Harper A, Davis GL, Vierling J, Lieblein L, et al. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl 2006;12(12 Suppl. 3):S128-S136.
12. Otto G, Herber S, Heise M, Lohse AW, Monch C, Bittinger F, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006;12:1260-1267.
13. Bhat M, Hassanain M, Simoneau E, Tzimas GN, Chaudhury P, Deschenes M, et al. Magnitude of change in alpha-fetoprotein in response to transarterial chemoembolization predicts survival in patients undergoing liver transplantation for hepatocellular carcinoma. Curr Oncol 2013;20:265-272.
14. Otto G, Schuchmann M, Hoppe-Lotichius M, Heise M, Weinmann A, Hansen T, et al. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE? J Hepatol 2013;59:279-284.